ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

[1]  N. Chen,et al.  Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. , 2019, Journal of medicinal chemistry.

[2]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[3]  Shan Zhu,et al.  Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma , 2019, Journal of Cancer Research and Clinical Oncology.

[4]  R. Yaeger,et al.  Targeting Alterations in the RAF-MEK Pathway. , 2019, Cancer discovery.

[5]  L. Bryan,et al.  Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date , 2018, OncoTargets and therapy.

[6]  S. Cook,et al.  ERK1/2 inhibitors: New weapons to inhibit the RAS‐regulated RAF‐MEK1/2‐ERK1/2 pathway , 2018, Pharmacology & therapeutics.

[7]  Ton Wang,et al.  BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers , 2018, Drugs.

[8]  Jeffrey W. Clark,et al.  Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. , 2018, Cancer discovery.

[9]  Min Huang,et al.  Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy , 2018, Acta pharmaceutica Sinica. B.

[10]  A. Markham.  Copanlisib: First Global Approval , 2017, Drugs.

[11]  R. Sullivan,et al.  Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma , 2017, Clinical Cancer Research.

[12]  A. Azmi,et al.  Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer , 2017, Oncotarget.

[13]  M. Souweidane,et al.  Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells , 2017, Translational oncology.

[14]  R. Scolyer,et al.  Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? , 2016, European journal of cancer.

[15]  Dolores Diaz,et al.  Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. , 2016, Journal of medicinal chemistry.

[16]  S. Rajagopal,et al.  Determination of ulixertinib in mice plasma by LC-MS/MS and its application to a pharmacokinetic study in mice. , 2016, Journal of pharmaceutical and biomedical analysis.

[17]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[18]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[19]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[20]  H. Soares,et al.  Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance , 2014, Molecular Cancer Therapeutics.

[21]  R. Neve,et al.  AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. , 2014, Cancer research.

[22]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[23]  K. Flaherty,et al.  BRAF in Melanoma: Current Strategies and Future Directions , 2013, Clinical Cancer Research.

[24]  V. Sondak,et al.  Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma , 2013, Nature Reviews Clinical Oncology.

[25]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[26]  R. Sullivan,et al.  Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.

[27]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[28]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[29]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[30]  Kwang-Hyun Cho,et al.  The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor. , 2012, Journal of molecular cell biology.

[31]  L. Donehower,et al.  Mouse Tissues that Undergo Neoplastic Progression after K-Ras Activation Are Distinguished by Nuclear Translocation of phospho-Erk1/2 and Robust Tumor Suppressor Responses , 2012, Molecular Cancer Research.

[32]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[33]  Stephen L. Abrams,et al.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.

[34]  Rony Seger,et al.  The ERK Cascade: Distinct Functions within Various Subcellular Organelles. , 2011, Genes & cancer.

[35]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[36]  J. Lehár,et al.  High-order combination effects and biological robustness , 2008, Molecular systems biology.

[37]  P. Pandolfi,et al.  Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. , 2007, Cancer research.

[38]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[39]  L. Cantley,et al.  ERK Negatively Regulates the Epidermal Growth Factor-mediated Interaction of Gab1 and the Phosphatidylinositol 3-Kinase* , 2002, The Journal of Biological Chemistry.

[40]  Dennis C. Friedrich,et al.  MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.

[41]  A. McKenna,et al.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.